1. A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management. (2nd January 2020) Authors: Grine, L.; de la Brassinne, M.; Ghislain, P.‐D.; Hillary, T.; Lambert, J.; Segaert, S.; Willaert, F.; Lambert, J. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 4(2020) Page Start: 676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study. (25th May 2020) Authors: Fougerousse, A.‐C.; Ghislain, P.‐D.; Reguiai, Z.; Maccari, F.; Parier, J.; Bouilly Auvray, D.; Chaby, G.; Pallure, V.; Schmutz, J.‐L.; Clément, C.; Jacobzone, C.; Begon, E.; Esteve, E. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 10(2020) Page Start: e644 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis. (5th February 2020) Authors: Merola, J.F.; Ghislain, P.‐D.; Dauendorffer, J.N.; Potts Bleakman, A.; Brnabic, A.J.M.; Burge, R.; Riedl, E. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 6(2020) Page Start: 1257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis. (February 2014) Authors: Reich, K.; Puig, L.; Paul, C.; Kragballe, K.; Luger, T.; Lambert, J.; Chimenti, S.; Girolomoni, G.; Nicolas, J.‐F.; Rizova, E.; Brunori, M.; Mistry, S.; Bergmans, P.; Barker, J.; Adamski, Z.; Altomare, G.; Aricò, M.; Aste, N.; Aubin, F.; Augustin, M. Journal: British journal of dermatology Issue: Volume 170:Number 2(2014:Feb.) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis. (1st February 2014) Authors: Reich, K.; Puig, L.; Paul, C.; Kragballe, K.; Luger, T.; Lambert, J.; Chimenti, S.; Girolomoni, G.; Nicolas, J.‐F.; Rizova, E.; Brunori, M.; Mistry, S.; Bergmans, P.; Barker, J.; Adamski, Z.; Altomare, G.; Aricò, M.; Aste, N.; Aubin, F.; Augustin, M. Journal: British journal of dermatology Issue: Volume 170:Number 2(2014:Feb.) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. (1st May 2017) Authors: Sampogna, F.; Puig, L.; Spuls, P.; Girolomoni, G.; Radtke, M.A.; Kirby, B.; Brunori, M.; Bergmans, P.; Smirnov, P.; Rundle, J.; Lavie, F.; Paul, C.; Affleck, A.; Antoniou, C.; Ayala, F.; Bakulev, A.; Bam, E.; Belinchon, I.; Bewley, A.; Botella, R. Journal: British journal of dermatology Issue: Volume 176:Number 5(2017) Page Start: 1195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab demonstrated sustained retention, effectiveness and safety in a real‐world setting in patients with moderate‐to‐severe plaque psoriasis: long‐term results from an interim analysis of the SERENA study. (4th July 2022) Authors: Augustin, M.; Sator, P.G.; von Kiedrowski, R.; Conrad, C.; Rigopoulos, D.; Romanelli, M.; Ghislain, P.‐D.; Torres, T.; Ioannides, D.; Aassi, M.; Schulz, B.; Jagiello, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 10(2022) Page Start: 1796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study. (1st December 2019) Authors: Thaçi, D.; Papp, K.; Marcoux, D.; Weibel, L.; Pinter, A.; Ghislain, P.‐D.; Landells, I.; Hoeger, P.H.; Unnebrink, K.; Seyger, M.M.B.; Williams, D.A.; Rubant, S.; Philipp, S. Journal: British journal of dermatology Issue: Volume 181:Number 6(2019) Page Start: 1177 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study. (25th July 2019) Authors: Thaçi, D.; Papp, K.; Marcoux, D.; Weibel, L.; Pinter, A.; Ghislain, P.‐D.; Landells, I.; Hoeger, P.H.; Unnebrink, K.; Seyger, M.M.B.; Williams, D.A.; Rubant, S.; Philipp, S. Journal: British journal of dermatology Issue: Volume 181:Number 6(2019) Page Start: 1177 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. (19th July 2022) Authors: de Graaf, M.; Janmohamed, S.R.; Schuttelaar, M.L.A.; Agner, T.; Alfonso, J.H.; De Schepper, S.; Deleuran, M.; Despontin, K.; Elenius, V.; Ghislain, P.‐D.; Huilaja, L.; Johansson, E.K.; Kvenshagen, B.K.; Mandelin, J.M.; Olset, H.; Svensson, A.; van Tuyll van Serooskerken, A.M.; Thyssen, J.P.; Vest... Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 11(2022) Page Start: 2153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗